Enovis (ENOV) Competitors $30.98 -0.46 (-1.46%) Closing price 03:59 PM EasternExtended Trading$31.34 +0.36 (+1.16%) As of 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENOV vs. DOV, IRTC, GKOS, BLCO, TMDX, SLNO, NVST, LIVN, WRBY, and INSPShould you be buying Enovis stock or one of its competitors? The main competitors of Enovis include Dover (DOV), iRhythm Technologies (IRTC), Glaukos (GKOS), Bausch + Lomb (BLCO), TransMedics Group (TMDX), Soleno Therapeutics (SLNO), Envista (NVST), LivaNova (LIVN), Warby Parker (WRBY), and Inspire Medical Systems (INSP). Enovis vs. Its Competitors Dover iRhythm Technologies Glaukos Bausch + Lomb TransMedics Group Soleno Therapeutics Envista LivaNova Warby Parker Inspire Medical Systems Enovis (NYSE:ENOV) and Dover (NYSE:DOV) are related companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership. Is ENOV or DOV more profitable? Dover has a net margin of 29.29% compared to Enovis' net margin of -37.80%. Dover's return on equity of 18.19% beat Enovis' return on equity.Company Net Margins Return on Equity Return on Assets Enovis-37.80% 6.78% 3.73% Dover 29.29%18.19%9.86% Do institutionals & insiders have more ownership in ENOV or DOV? 98.5% of Enovis shares are held by institutional investors. Comparatively, 84.5% of Dover shares are held by institutional investors. 2.7% of Enovis shares are held by insiders. Comparatively, 1.2% of Dover shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has higher valuation & earnings, ENOV or DOV? Dover has higher revenue and earnings than Enovis. Enovis is trading at a lower price-to-earnings ratio than Dover, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnovis$2.11B0.84-$825.49M-$14.25-2.17Dover$7.75B3.20$2.70B$16.5810.89 Which has more risk & volatility, ENOV or DOV? Enovis has a beta of 1.7, meaning that its stock price is 70% more volatile than the S&P 500. Comparatively, Dover has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Does the media refer more to ENOV or DOV? In the previous week, Dover had 20 more articles in the media than Enovis. MarketBeat recorded 30 mentions for Dover and 10 mentions for Enovis. Enovis' average media sentiment score of 1.45 beat Dover's score of 0.97 indicating that Enovis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enovis 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dover 21 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive Do analysts recommend ENOV or DOV? Enovis presently has a consensus target price of $51.00, indicating a potential upside of 64.62%. Dover has a consensus target price of $213.92, indicating a potential upside of 18.49%. Given Enovis' stronger consensus rating and higher probable upside, equities research analysts plainly believe Enovis is more favorable than Dover.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enovis 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Dover 0 Sell rating(s) 5 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.58 SummaryDover beats Enovis on 10 of the 16 factors compared between the two stocks. Get Enovis News Delivered to You Automatically Sign up to receive the latest news and ratings for ENOV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENOV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENOV vs. The Competition Export to ExcelMetricEnovisMEDICAL INFO SYS IndustryMedical SectorNYSE ExchangeMarket Cap$1.77B$2.10B$5.76B$21.09BDividend YieldN/AN/A4.40%3.55%P/E Ratio-2.1737.4330.1928.89Price / Sales0.8413.49474.1753.01Price / Cash1.6453.5525.7818.23Price / Book0.6910.749.424.69Net Income-$825.49M-$63.67M$3.27B$995.89M7 Day Performance5.00%0.81%2.04%1.91%1 Month Performance12.52%0.59%3.58%1.73%1 Year Performance-32.70%24.48%30.08%10.20% Enovis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENOVEnovis4.4721 of 5 stars$30.98-1.5%$51.00+64.6%-31.8%$1.77B$2.11B-2.177,367Insider TradeDOVDover4.9225 of 5 stars$177.08+0.3%$213.92+20.8%-0.9%$24.21B$7.75B10.6824,000IRTCiRhythm Technologies1.3085 of 5 stars$157.93-1.7%$157.30-0.4%+141.6%$5.16B$591.84M-53.902,000Insider TradeGKOSGlaukos4.7186 of 5 stars$89.47-0.4%$127.42+42.4%-29.1%$5.15B$383.48M-54.22780Analyst RevisionBLCOBausch + Lomb1.6225 of 5 stars$14.49-0.4%$15.56+7.4%-8.3%$5.15B$4.79B-18.5713,500TMDXTransMedics Group2.8071 of 5 stars$125.65-1.5%$123.00-2.1%-31.8%$4.35B$441.54M65.10210Positive NewsAnalyst ForecastSLNOSoleno Therapeutics4.6217 of 5 stars$68.09-4.9%$114.30+67.9%+51.5%$3.81BN/A-16.4530News CoverageNVSTEnvista3.7171 of 5 stars$20.75+0.5%$20.92+0.9%+15.9%$3.43B$2.51B64.8312,300LIVNLivaNova1.6401 of 5 stars$53.27-0.8%$59.29+11.3%+20.0%$2.93B$1.25B-13.692,900News CoveragePositive NewsWRBYWarby Parker2.1914 of 5 stars$27.38+0.9%$24.06-12.1%+74.2%$2.85B$771.32M-391.093,780Positive NewsAnalyst UpgradeINSPInspire Medical Systems4.9376 of 5 stars$88.28+0.6%$165.62+87.6%-50.0%$2.60B$802.80M51.031,246Positive News Related Companies and Tools Related Companies Dover Competitors iRhythm Technologies Competitors Glaukos Competitors Bausch + Lomb Competitors TransMedics Group Competitors Soleno Therapeutics Competitors Envista Competitors LivaNova Competitors Warby Parker Competitors Inspire Medical Systems Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ENOV) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enovis Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Enovis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access